Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> JAK/STAT Signaling >> EGFR

EGFR

EGFR (epidermal growth factor receptor) is the cell-surface receptor of its specific ligands, including epidermal growth factor and TGFα (transforming growth factor α) and is a receptor tyrosine kinase.

Products for  EGFR

  1. Cat.No. Product Name Information
  2. GC38006 β-Hydroxyisovalerylshikonin Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermium radix, acts as a potent inhibitor of protein tyrosine kinases (PTK), with IC50s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively. Beta-hydroxyisovalerylshikonin is effective against a wide variety of tumor cell lines, and most efficiently induces cell-death in NCI-H522 and DMS114 cells. β-Hydroxyisovalerylshikonin Chemical Structure
  3. GC73049 (Rac)-JBJ-04-125-02 acetate (Rac)-JBJ-04-125-02 acetate is the racemate of JBJ-04-125-02. (Rac)-JBJ-04-125-02 acetate Chemical Structure
  4. GC63797 (S)-Sunvozertinib

    (S)-DZD9008

     (S)-Sunvozertinib ((S)-DZD9008), the S-enantiomer of Sunvozertinib, shows inhibitory activity against EGFR exon 20 NPH and ASV insertions, EGFR L858R/T790M mutation and Her2 exon20 YVMA insertion (IC50=51.2 nM, 51.9 nM, 1 nM, and 21.2 nM, respectively). (S)-Sunvozertinib also inhibits BTK. (S)-Sunvozertinib Chemical Structure
  5. GC13257 AC480 (BMS-599626)

    BMS-599626

     AC480 (BMS-599626) (AC480) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC50s of 20 and 30 nM, respectively. AC480 (BMS-599626) displays ~8-fold less potent to HER4 (IC50=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. AC480 (BMS-599626) inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy. AC480 (BMS-599626) Chemical Structure
  6. GC11892 AEE788 (NVP-AEE788)

    NVP-AEE788

     AEE788 (NVP-AEE788) is an inhibitor of the EGFR and ErbB2 with IC50 values of 2 and 6 nM, respectively. AEE788 (NVP-AEE788) Chemical Structure
  7. GC11744 AG 555

    Tyrphostin AG-555, Tyrphostin B46

     Potent EGFR-kinase inhibitor AG 555 Chemical Structure
  8. GC13168 AG 825

    Tyrphostin AG825

     Selective ErbB2 inhibitor AG 825 Chemical Structure
  9. GC14494 AG 99

    Tyrphostin 46, Tyrphostin AG-99

     AG 99 ((E)-Tyrphostin 46) is a potent EGFR inhibitor. AG 99 Chemical Structure
  10. GC17226 AG-1478

    Tyrphostin AG-1478; AG 1478; NSC 693255; AG1478

     EGFR inhibitor,potent and selective AG-1478 Chemical Structure
  11. GC12864 AG-1557

    Tyrphostin AG-1557

     inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase AG-1557 Chemical Structure
  12. GC17647 AG-18

    RG50810, RG50858, TX 825, Tyrphostin 23, Tyrphostin AG18

     AG-18 (Tyrphostin A23) is an EGFR inhibitor with an IC50 and Kiof 35 and 11 μM, respectively. AG-18 Chemical Structure
  13. GC13854 AG-490 (Tyrphostin B42)

    Tyrphostin AG-490

     AG-490 (Tyrphostin B42) is EGFR inhibitor with IC50 of 0.1 µM, AG-490 also has an inhibitory effect on JAK2. AG-490 (Tyrphostin B42) Chemical Structure
  14. GC64398 Almonertinib mesylate

    HS-10296 mesylate

     Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer. Almonertinib mesylate Chemical Structure
  15. GC67749 Amivantamab

    JNJ-61186372

    Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity

     Amivantamab Chemical Structure
  16. GC74504 Anbenitamab

    KN-026

     Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab Chemical Structure
  17. GC17283 AP26113

    Brigatinib

     AP26113 (Brigatinib analog) is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1. AP26113 Chemical Structure
  18. GC12478 ARRY-380

    ARRY380; ARRY 380

     ARRY-380, an inhibitor of EGFR (ErbB1), is extracted from patent WO2015153959A2, compound 249. ARRY-380 is a potent, selective, ATP-competitive, orally active inhibitor of HER2. ARRY-380 Chemical Structure
  19. GC11691 AST-1306

    AST1306; AST 1306

     AST-1306 (AST-1306) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. AST-1306 also inhibits ErbB4 with an IC50 of 0.8 nM. AST-1306 is an anilino-quinazoline compound and has anti-cancer activity. AST-1306 Chemical Structure
  20. GC15669 AST-1306 TsOH

    Allitinib

     AST-1306 TsOH (AST-1306 (TsOH)) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. AST-1306 TsOH also inhibits ErbB4 with an IC50 of 0.8 nM. AST-1306 TsOH is an anilino-quinazoline compound and has anti-cancer activity AST-1306 TsOH Chemical Structure
  21. GC33096 AST2818 mesylate

    AST2818

     Alflutinib (Furmonertinib) mesylate is is a potent inhibitor of EGFR. Alflutinib (Furmonertinib) mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Alflutinib (Furmonertinib) mesylate has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC). AST2818 mesylate Chemical Structure
  22. GC35413 Astragaloside VI Astragaloside VI could activate EGFR/ERK signalling pathway to improve wound healing. Astragaloside VI Chemical Structure
  23. GC35435 AV-412

    MP-412

     A dual inhibitor of EGFR and HER2 AV-412 Chemical Structure
  24. GC35436 AV-412 free base

    MP-412 free base

     AV-412 free base (MP-412 free base) is an EGFR inhibitor with IC50s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively. AV-412 free base Chemical Structure
  25. GC19044 Avitinib maleate

    A pyrrolopyrimidine-based irreversible EGFR inhibitor

     Avitinib maleate Chemical Structure
  26. GC12955 AZ5104 EGFR inhibitor AZ5104 Chemical Structure
  27. GC16308 AZD-9291

    osimertinib

     AZD-9291 (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. AZD-9291 overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. AZD-9291 Chemical Structure
  28. GC16698 AZD-9291 mesylate AZD-9291 mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. AZD-9291 mesylate Chemical Structure
  29. GC13143 AZD3759

    AZD3759

     AZD3759 (AZD3759) is a potent, orally active, central nervous system-penetrant, EGFR inhibitor. At Km ATP concentrations, the IC50s are 0.3, 0.2, and 0.2 nM for EGFRwt, EGFRL858R, and EGFRexon 19Del, respectively. AZD3759 Chemical Structure
  30. GC13761 AZD8931 (Sapitinib)

    Sapitinib

     AZD8931 (Sapitinib) (AZD-8931) is a reversible, ATP competitive EGFR inhibitor of with IC50s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively. AZD8931 (Sapitinib) Chemical Structure
  31. GC74510 Bafisontamab

    EMB-01

     Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity. Bafisontamab Chemical Structure
  32. GC74512 Barecetamab

    ISU-104

     Barecetamab (ISU-104) is a fully human anti-ErbB3 monoclonal antibody. Barecetamab Chemical Structure
  33. GC64302 BAY 2476568 BAY 2476568 is a potent and selective EGFR inhibitor, with IC50s of < 0.2 nM for wild-type EGFR and several mutations (EGFRR ex20insSVD, EGFRR ex20insASV, EGFRR ex20insNPG). BAY 2476568 Chemical Structure
  34. GC74436 Becotatug

    JMT-101

     Becotatug (JMT-101) is an IgG1 antibody targeting EGFR that can also be conjugated to Afatinib and Osimertinib as a synthetic ADC. Becotatug Chemical Structure
  35. GC64017 Befotertinib

    D-0316

     Befotertinib (D-0316) is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC). Befotertinib Chemical Structure
  36. GC33172 BGB-102 (JNJ-26483327) BGB-102 (JNJ-26483327) is a potent multi-kinase inhibitor against EGFR, HER2, and HER4 with IC50s of 9.6 nM, 18 nM and 40.3 nM, respectively. BGB-102 (JNJ-26483327) Chemical Structure
  37. GC19066 BGB-283 BGB-283 is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively. BGB-283 Chemical Structure
  38. GC68759 BI-1622

    BI-1622 is an orally effective and highly selective HER2 (ERBB2) inhibitor with an IC50 of 7 nM. BI-1622 has a selectivity for EGFR greater than 25-fold. In transplant mouse models of H2170 and PC9 cells, BI-1622 showed high in vivo anti-tumor effects and has good activity molecular metabolism and pharmacokinetic properties.

     BI-1622 Chemical Structure
  39. GC38402 BI-4020 A fourth-generation and non-covalent EGFR tyrosine kinase inhibitor BI-4020 Chemical Structure
  40. GC68762 BI-4142

    BI-4142 is an effective, highly selective, orally active HER2 inhibitor with an IC50 value of 5 nM.

     BI-4142 Chemical Structure
  41. GC63910 BLU-945 BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC). BLU-945 Chemical Structure
  42. GC10944 Butein

    2’,3,4,4’tetrahydroxy Chalcone

     Protein kinase inhibitor Butein Chemical Structure
  43. GC12910 Canertinib (CI-1033) Canertinib (CI-1033) (CI-1033;PD-183805) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM. Canertinib (CI-1033) Chemical Structure
  44. GC34217 Cetuximab (C225)

    C225

     Cetuximab is a chimeric monoclonal antibody generated from fusion of the variable region of the murine anti-EGFR monoclonal antibody M225 and the human IgG1 constant region. Cetuximab (C225) Chemical Structure
  45. GC15950 CGP 52411

    CGP 52411, 4,5-Dianilinophthalimide

     EGFR inhibitor CGP 52411 Chemical Structure
  46. GC25219 CH7233163 CH7233163 is a non-covalent ATP competitive inhibitor of EGFR-tyrosine kinase with antitumor activities against tumor with EGFR-Del19/T790M/C797S. CH7233163 Chemical Structure
  47. GC35684 CHMFL-EGFR-202 CHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC50s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. CHMFL-EGFR-202 exhibits ?10-fold selectivity for EGFR L858R/T790M against the EGFR wild-type in cells. CHMFL-EGFR-202 adopts a covalent “DFG-in-C-helix-out” inactive binding conformation with EGFR, with strong antiproliferative effects against EGFR mutant-driven nonsmall-cell lung cancer (NSCLC) cell lines. CHMFL-EGFR-202 Chemical Structure
  48. GC74542 Cinrebafusp alfa

    PRS 343

     Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa Chemical Structure
  49. GC17790 CL-387785 (EKI-785)

    EKB-785, EKI-785, WAY-EKI-785

     CL-387785 (EKI-785)(EKI785; WAY-EKI 785) is an irreversible inhibitor of EGFR with IC50 of 370 pM. CL-387785 (EKI-785) Chemical Structure
  50. GC11264 CNX-2006

    mutant-EGFR inhibitor, selective and irreversible

     CNX-2006 Chemical Structure
  51. GC13091 CP-724714 HER2 inhibitor,potent and selective CP-724714 Chemical Structure
  52. GC38180 Cyasterone Cyasterone Chemical Structure
  53. GC10225 Dacomitinib (PF299804, PF299)

    PF-00299804; PF-299804; PF 299804; PF 00299804

     Dacomitinib (PF299804, PF299) (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively. Dacomitinib (PF299804, PF299) Chemical Structure
  54. GC72889 Dacomitinib hydrate

    PF-00299804 hydrate; PF-299804 hydrate

     Dacomitinib (PF-00299804) drate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate Chemical Structure
  55. GC74602 Depatuxizumab

    ABT-806

     Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab Chemical Structure
  56. GC73019 Depatuxizumab mafodotin

    ABT-414

     Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) that specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin Chemical Structure
  57. GC73335 DHFR-IN-4 DHFR-IN-4 is a potent didrofolate reductase (DHFR) inhibitor with an IC50 value of 123 nM. DHFR-IN-4 Chemical Structure
  58. GC68986 Disitamab

    RC48-0

    Disitamab (RC48-0) is a humanized monoclonal antibody that targets HER2. Disitamab can be used to synthesize antibody-drug conjugates (ADCs), such as Disitamab vedotin.

     Disitamab Chemical Structure
  59. GC64039 Disitamab vedotin

    Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity.

     Disitamab vedotin Chemical Structure
  60. GC69000 Dosimertinib-d5 mesylate

    Dosimertinib-d5 (mesylate) is an effective orally active EGFR inhibitor. It reduces the expression of p-EGFR and p-ERK proteins. Dosimertinib-d5 (mesylate) exhibits anti-proliferative and anti-tumor activity. Dosimertinib-d5 (mesylate) has potential for research in non-small cell lung cancer (NSCLC).

     Dosimertinib-d5 mesylate Chemical Structure
  61. GC72453 Duligotuzumab Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody that specifically targets Her3 (ErbB3). Duligotuzumab Chemical Structure
  62. GC73544 DZD1516 DZD1516 is a potent and selective HER2 inhibitor (IC50=0.56 nM) with good blood-brain permeability. DZD1516 Chemical Structure
  63. GC66432 EAI001 EAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC50 value of 24 nM for EGFRL858R/T790M. EAI001 can be used for research of cancer. EAI001 Chemical Structure
  64. GC12281 EAI045 Inhibitor of L858R/T790M EGFR mutants EAI045 Chemical Structure
  65. GC16321 EGF816 EGF816 (EGF816) is a covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min-1 on EGFR(L858R/790M) mutant, respectively. EGF816 Chemical Structure
  66. GC35965 EGFR mutant-IN-1 EGFR mutant-IN-1, a 5-methylpyrimidopyridone derivative, is a potent and selective EGFRL858R/T790M/C797S mutant inhibitor with an IC50 of 27.5 nM, while being a significantly less potent for EGFRWT (IC50 >1.0 μM). EGFR mutant-IN-1 Chemical Structure
  67. GC65572 EGFR Protein Tyrosine Kinase Substrate EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate. EGFR Protein Tyrosine Kinase Substrate Chemical Structure
  68. GC73274 EGFR T790M/L858R-IN-2 EGFR T790M/L858R-IN-2 is a potent and selective EGFRT790M/L858R inhibitor with IC50 values of 3.5, 1290 nM for EGFRT790M/L858R, EGFR WT, respectively. EGFR T790M/L858R-IN-2 Chemical Structure
  69. GC64497 EGFR-IN-17 EGFR-IN-17 is a potent and selective inhibitor of the epidermal growth factor receptor ( IC50 0.0002 μM) to overcome C797S-mediated resistance. EGFR-IN-17 Chemical Structure
  70. GC33195 EGFR-IN-2 EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation EGFR inhibitor. EGFR-IN-2 Chemical Structure
  71. GC19132 EGFR-IN-3 EGFR-IN-3 is a third-generation EGFR TKI, with GI50 values of 5 nM (EGFR L858R/T790M), 10 nM (EGFR del19) and 689 nM (EGFR WT), respectively. EGFR-IN-3 has the potential for NSCLC research. EGFR-IN-3 Chemical Structure
  72. GC66428 EGFR-IN-5 EGFR-IN-5 is a EGFR inhibitor with IC50s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFRL858R, EGFRL858R/T790M, and EGFRL858R/T790M/C797S, respectively. EGFR-IN-5 Chemical Structure
  73. GC68440 EGFR-IN-69 EGFR-IN-69 Chemical Structure
  74. GC35966 EGFR-IN-7 EGFR-IN-7 is a potent, selective and orally active EGFR kinase inhibitor. EGFR-IN-7 has inhibitory effect for for EGFR (WT) and EGFR (mutant C797S/T790M/L858R) with IC50 values of 7.92 nM and 0.218 nM, respectively. EGFR-IN-7 shows anti-tumor activity. EGFR-IN-7 can be used for the research of various cancers. EGFR-IN-7 Chemical Structure
  75. GC69043 EGFR-IN-70

    EGFR-IN-70 (compound 18j) is an effective EGFR inhibitor with IC50 values of 23.6 and 307.5 nM for EGFRLR/TM/CS and EGFRWT, respectively. It has anti-proliferative activity and inhibits the phosphorylation of EGFR. EGFR-IN-70 can be used in cancer research.

     EGFR-IN-70 Chemical Structure
  76. GC65974 EGFR-IN-9 EGFR-IN-9 (Compound 8) is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity. EGFR-IN-9 Chemical Structure
  77. GC73753 EGFR/AURKB-IN-1 EGFR/AURKB-IN-1 (compound 7) is a dual-targeted EGFR/AURKB inhibitor, and inhibits the phpsphorylations of L858R EGFR and AURKB with IC50s of 0.07 and 1.1, respectively. EGFR/AURKB-IN-1 Chemical Structure
  78. GC73415 EGFR/HER2-IN-9 EGFR/HER2-IN-9 (Compound 1) is an EGFR and HER2 inhibitor with IC50s of 3.2, 8.3 and 14 nM against EGFR, EGFR T790M and HER2, respectively. EGFR/HER2-IN-9 Chemical Structure
  79. GC74615 Elgemtumab

    LJM716

     Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab Chemical Structure
  80. GC33048 Epertinib (S-22611) Epertinib (S-22611) (S-22611) is a potent, oral, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4, with IC50s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib (S-22611) shows potent antitumor activity. Epertinib (S-22611) Chemical Structure
  81. GC38350 Epertinib hydrochloride

    S-22611 hydrochloride

     Epertinib hydrochloride (S-22611 hydrochloride) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4, with IC50s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib hydrochloride shows potent antitumor activity. Epertinib hydrochloride Chemical Structure
  82. GC69075 Epidermal growth factor (EGF) (phosphate)

    Epidermal growth factor (EGF) is an effective epidermal growth factor that stimulates the proliferation of skin cells and is used for wound healing applications.

     Epidermal growth factor (EGF) (phosphate) Chemical Structure
  83. GC74374 ErbB-2-binding peptide

    HER2-binding peptide

     ErbB-2-binding peptide (HER2-binding peptide) is a tumor-binding peptide. ErbB-2-binding peptide Chemical Structure
  84. GC36003 Erlotinib mesylate EGFR inhibitor Erlotinib mesylate Chemical Structure
  85. GC65992 FGFR2-IN-3 FGFR2-IN-3 is an orally active selective inhibitor of FGFR2. FGFR2-IN-3 Chemical Structure
  86. GC65991 FGFR2-IN-3 hydrochloride FGFR2-IN-3 hydrochloride is an orally active selective inhibitor of FGFR2. FGFR2-IN-3 hydrochloride Chemical Structure
  87. GC69111 Fidasimtamab

    IBI-315; BH2950

    Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that can simultaneously target, bind and inhibit HER2 and PD-1 and their downstream signaling pathways, connecting PD-1 expressing T cells with HER2-expressing tumor cells. Fidasimtamab has potential immune-suppressive and anti-tumor activity.

     Fidasimtamab Chemical Structure
  88. GC36044 FIIN-3 FIIN-3 is an irreversible inhibitor of FGFR with an IC50 of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FIIN-3 Chemical Structure
  89. GC19509 Gefitinib-based PROTAC 3

    Gefitinib-based Proteolysis-targeting Chimera 3

     A VHL-recruiting PROTAC Gefitinib-based PROTAC 3 Chemical Structure
  90. GC14102 Genistein

    CI-75610, NSC 36586

     Genistein is an isoflavone belonging to the flavonoid group of compounds and is found in a number of plants. Genistein Chemical Structure
  91. GC73975 HNPMI HNPMI is an inhibitor of EGFR and has cytotoxic effects on tumor cells. HNPMI Chemical Structure
  92. GC33053 HS-10296 hydrochloride Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. HS-10296 hydrochloride shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). HS-10296 hydrochloride is used for the research of the non-small cell lung cancer. HS-10296 hydrochloride Chemical Structure
  93. GC73382 HX103 HX103 is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-based fluorogenic probe. HX103 Chemical Structure
  94. GC17982 Icotinib

    BPI 2009H

     EGFR tyrosine kinase inhibitor Icotinib Chemical Structure
  95. GC74484 Imgatuzumab

    RG 7160; RO 5083945; Anti-EGFR Recombinant Antibody

     Imgatuzumab (RG 7160) is a humanized monoclonal antibody against the EGFR. Imgatuzumab Chemical Structure
  96. GC74626 Inetetamab Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab Chemical Structure
  97. GC74485 Intetumumab

    CNTO 95; Anti-Human CD51 Recombinant Antibody

     Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab Chemical Structure
  98. GC74565 Izalontamab

    SI-B001

     Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab Chemical Structure
  99. GC67690 JBJ-09-063 hydrochloride

    JBJ-09-063 hydrochloride is a mutation selective allosteric EGFR inhibitor

     JBJ-09-063 hydrochloride Chemical Structure
  100. GC67860 JBJ-09-063 TFA JBJ-09-063 TFA Chemical Structure
  101. GC65436 JND3229 JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma. JND3229 Chemical Structure

Items 1 to 100 of 194 total

per page
  1. 1
  2. 2

Set Descending Direction